Journal of Cancer Epidemiology and Prevention

Open access Commentary

# Incorporating Marine-based Cancer Drugs based on Pharmacology

**Liang Tian***

*Department of Radio Oncology, Peking University, China*

## DESCRIPTION

Chemotherapy can be difficult to control because, at the wrong dose, it can't stop the growth and, at the wrong dose, the patient can't handle the side effects. The estimated body surface area serves as the standard basis for the dosage of chemotherapy. A 1916 study that attempted to translate medicinal doses established in laboratory animals into comparable human doses provided the basis for this formula. The concentrate just included nine human members. At the point when it was first presented during the 1950s, the BSA equation was acknowledged as the authority standard for chemotherapy dosing without any another option. The validity of this method for determining uniform dosages has been discussed because the recipe only takes into accounts the individual's level and weight. Drug assimilation and leeway are significantly impacted by age, sex, digestion, illness, organ capacity, drug-to-tranquilize interactions, hereditary characteristics, and weight. These factors also have a significant impact on the actual grouping of the medication in the individual's circulatory system. Similar to this, there is a significant vacillation in the primary chemotherapy drug center among BSA-dosed patients, and this vacillation has been demonstrated to be greater than multiple times for certain medications. To put it another way, on the off chance that two individuals take a similar measure of a medication, one individual's circulation system fixation might be multiple times higher or lower than the other individual's. This assortment, which was displayed in a survey including 14 ordinary chemotherapy drugs, is common of numerous prescriptions oversaw by BSA. The term "applicant polymorphism search" refers to the process of locating polymorphic DNA groupings within particular characteristics that might make candidates for particular characteristics. This approach aims to pinpoint a compound's pharmacokinetic or pharmacodynamic characteristics down to a candidate polymorphism level in pharmacogenomics. You can use this kind of data to choose the best treatment options for a patient. To fathom the likely practical effect of a polymorphic DNA grouping, quality quieting can be utilized. Previously, siRNAs were frequently used to suppress gene expression; even more lately, anyway, they have been proposed for use in research and the creation of therapeutics. Clustered Regularly Interspaced Short Palindromic Repeats is a novel strategy. The enzyme and CRISPR are the foundation of the technology. This framework excels at quality quieting tasks because it can identify and separate specific DNA groups.

Nearly every kind of solid tumor, including brain, breast, cervix, larynx, liver, lung, pancreas, prostate, skin, stomach, uterus, and soft tissue sarcomas, can be treated with radiation therapy. Additionally, lymphoma and leukemia can be treated with radiation therapy. The radiation portion to each still up in the air by different elements, including the radio-sensitivity of every sort of malignant growth and the presence of adjacent tissues and organs that could be harmed by radiation. Radiation therapy has its drawbacks, just like any other treatment. Because it damages the salivary glands and reduces the amount of saliva produced, radiation therapy can cause dry mouth. This is interesting because the salivary organs will occasionally continue to function normally after treatment. Radiation-related dry mouth can be a problem for a long time. If the growth was discovered in its early stages or in a weak area, radiation may not be an option for treatment because it may damage organs at successful portions.

## ACKNOWLEDGEMENT

None.

## CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

| | | | |
|---|---|---|---|
| **Received:** | 31-January-2023 | **Manuscript No:** | IPJCEP-23-16268 |
| **Editor assigned:** | 02-February-2023 | **PreQC No:** | IPJCEP-23-16268 (PQ) |
| **Reviewed:** | 16-February-2023 | **QC No:** | IPJCEP-23-16268 |
| **Revised:** | 21-February-2023 | **Manuscript No:** | IPJCEP-23-16268 (R) |
| **Published:** | 28-February-2023 | **DOI:** | 10.36648/IPJCEP.23.08.006 |

**Corresponding author** Liang Tian, Department of Radio Oncology, Peking University, China, E-mail: tian_l@gmail.com

**Citation** Tian L (2023) Incorporating Marine-based Cancer Drugs based on Pharmacology. J Cancer Epidemiol Prev. 8:006.